Interleukin-10-regulated tumour tolerance in non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Lung cancer is the most life-threatening cancer type worldwide. Treatment options include surgery, radio- and chemotherapy, as well as the use of immunomodulatory antibodies. Interleukin (IL)-10 is an immunosuppressive cytokine involved in tumour immune escape. Immunohistochemistry (IHC) on human lung surgery tissue as well as human tumour cell line cultures, FACS analysis, real-time PCR and experimental lung cancer. Here we discovered a positive correlation between IL-10 and IL-10 receptor (IL-10R) expression in the lung with tumour diameter in patients with lung cancer (non-small cell lung cancer), the most life-threatening cancer type worldwide. IL-10 and IL-10R were found induced in cells surrounding the lung tumour cells, and IL-10R was mainly expressed on the surface of Foxp-3 + T-regulatory lymphocytes infiltrating the tumour of these patients where its expression inversely correlated with programmed cell death 1. These findings were confirmed in translational studies. In a human lung adenocarcinoma cell line, IL-10R was found induced under metabolic restrictions present during tumour growth, whereby IL-10 inhibited PDL1 and tumour cell apoptosis. These new findings suggest that IL-10 counteracts IFN-γ effects on PD1/PDL1 pathway, resulting in possible resistance of the tumour to anti-PD1/PDL1 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 1×
“We next found that HIF1-a correlated with IL-10R in the control region of SCC (Figure 4C), knowing that HIF1-a can cause metabolic cell reprogramming in cancer (DeBerardinis et al, 2008).”
BackgroundWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 3×
“…antigenpresenting cells (APC) (Huang et al, 1998; Sharma et al, 1999; Coussens and Werb, 2002; Jarnicki et al, 2006) and M1macrophages (Almatroodi et al, 2016), and in this context programmed death-1 (PD1) is regarded as an excellent marker of T-cell exhaustion (Wherry, 2011; Mandai et al, 2016).”
BackgroundGoldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655 · cited 1×
“Unfortunately, the frequently late clinical detection going along with high pathological stage and the absence of curative end-stage treatment options results in a low 5 years average survival rate (Naruke et al, 1988; Goldstraw et al, 2007).”
BackgroundChaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289 · cited 2×
“…0007 – 0920/17 FULL PAPER Keywords: non-small cell lung cancer; IL-10; IL-10R; PD1; PDL1 British Journal of Cancer (2017) 117, 1644–1655 | doi: 10.1038/bjc.2017.336 1644 www.bjcancer.com | DOI:10.1038/bjc.2017.336 NSCLC, are also capable of releasing IL-10 (Teng et al, 2011; Dennis et al, 2013).”
BackgroundInfluentialIL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines
Zeng, L., O’Connor, C., Zhang, J., Kaplan, A. M., & Cohen, D. A. (2010) · Cytokine · doi:10.1016/j.cyto.2009.11.015 · Cited by 59 · cited 1×
“Finally, incomplete surgery increases the level of IL-10 (Rybojad et al, 2013), which also has the potential to promote metastasis (Zeng et al, 2010).”
Background
Cited by
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692142 · Cited by 343
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Asare, P. F., Roscioli, E., Hurtado, P. R., Tran, H. B., Mah, C. Y., & Hodge, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01298 · Cited by 50
Cellular senescence in tumor immune escape: Mechanisms, implications, and therapeutic potential
You, L., & Wu, Q. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104628 · Cited by 21
Metadata
- Authors
- Vahl, J. M., Friedrich, J., Mittler, S., Trump, S., Heim, L., Kachler, K., Balabko, L., Fuhrich, N., Geppert, C.-I., Trufa, D. I., Sopel, N., Rieker, R., Sirbu, H., & Finotto, S.
- Venue
- British Journal of Cancer
- Published
- 2017-10-10
- Volume
- 117
- Issue
- 11
- Pages
- 1644-1655
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2761104268
- Cited by
- 105
- References
- 7
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/bjc.2017.336
- The paper
- Vahl, J. M., Friedrich, J., Mittler, S., Trump, S., Heim, L., Kachler, K., Balabko, L., Fuhrich, N., Geppert, C.-I., Trufa, D. I., Sopel, N., Rieker, R., Sirbu, H., & Finotto, S. (2017). Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2017.336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.